<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The severity of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) has not been completely studied </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed the prognostic significance of severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (neutrophils count &lt;0.5×10(9)/L) at diagnosis in 1109 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and low/intermediate-1 IPSS included in the Spanish <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> Registry </plain></SENT>
<SENT sid="2" pm="."><plain>Severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> was present at diagnosis in 48 of 1109 (4%) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> were most strongly represented within the groups of refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (40%) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blast type 1 (29%) </plain></SENT>
<SENT sid="4" pm="."><plain>Severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> had negative effects on the low/intermediate-1 risk group </plain></SENT>
<SENT sid="5" pm="."><plain>A significant difference in overall survival was observed between patients with severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (28 months) and patients with a neutrophil count higher than 0.5×10(9)/L (66 months) (p&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Also, severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> predicted a significantly reduced on <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (p&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>In the multivariate analysis, severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> retained its independent prognostic influence on overall survival [HR: 2.19, 95% CI (1.41-3.10), p&lt;0.0001] and <z:hpo ids='HP_0001909'>leukemia</z:hpo> free survival [HR: 3.51, 95% CI (1.97-6.26), p&lt;0.0001] </plain></SENT>
<SENT sid="8" pm="."><plain>The degree of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> should be considered as additional prognostic factor in low/intermediate-1 IPSS <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>